The Technical Analyst
ContraFect Corp [CFRX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
ContraFect Corp Price, Forecast, Insider, Ratings, Fundamentals & Signals
-27.95% $0.0500
America/New_York / 5 des 2023 @ 15:31
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 0.372 mill |
| EPS: | -10.83 |
| P/E: | -0.0046 |
| Earnings Date: | Nov 13, 2023 |
| SharesOutstanding: | 7.44 mill |
| Avg Daily Volume: | 0.263 mill |
| RATING 2024-01-02 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0046 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.0046 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0060 - 0.0640 ( +/- 82.98%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-02-14 | Messinger Michael | Buy | 25 000 | Options (Right to Buy) |
| 2022-05-17 | Barlow Jane F | Buy | 42 000 | Options (Right to Buy) |
| 2022-05-17 | Sucoff Cary | Buy | 42 000 | Options (Right to Buy) |
| 2022-05-17 | Otto Michael J. | Buy | 42 000 | Options (Right to Buy) |
| 2022-05-17 | Low David N. | Buy | 42 000 | Options (Right to Buy) |
| INSIDER POWER |
|---|
| 100.00 |
| Last 55 transactions |
| Buy: 2 642 000 | Sell: 9 700 000 |
Forecast:
01:40 - $-0.125
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.0500 (-27.95% ) |
| Volume | 0.910 mill |
| Avg. Vol. | 0.263 mill |
| % of Avg. Vol | 346.37 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CFRX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CFRX
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also initiated an expanded access program to provide Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.
Latest Press Releases
2023-10-16 07:30:00 - Press Release
Contrafect Announces Fda Clearance Of Cf-370 Ind Application To Proceed With Phase 1 Clinical Study
Cf-370 is the first engineered lysin therapeutic targeting gram-negative pathogens allowed to enter a human trial cf-370 is the first engineered lysin therapeutic targeting gram-negative pathogens allowed to enter a human trial
2023-09-19 08:30:00 - Press Release
Contrafect To Present At The Asm/escmid Joint Conference On Drug Development
Yonkers, new york, sept. 19, 2023 (globe newswire) -- contrafect corporation (nasdaq: cfrx), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (dlas), including lysins and amurin peptides, today announces that jane ambler, ph.d., the company's vice president of clinical microbiology, will be presenting at the asm/escmid joint conference on drug development to meet the challenge of antimicrobial resistance, which will be held in boston, ma from september 19-22, 2023.
2023-09-18 07:30:00 - Press Release
Contrafect Announces Submission Of Ind Application To The Fda For Its Development Candidate Cf-370
Yonkers, n.y., sept. 18, 2023 (globe newswire) -- contrafect corporation (nasdaq: cfrx), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (dlas), including lysins and amurin peptides, today announces that it submitted an investigational new drug (ind) application to the u.s. food and drug administration (fda) on september 15, 2023. the ind application supports a proposed indication for its intravenous (iv) antibacterial agent, cf-370, for treatment of hospital-acquired bacterial pneumonia (habp) and ventilator-associated bacterial pneumonia (vabp).
2023-08-28 08:00:00 - Press Release
Contrafect To Present At The World Anti-microbial Resistance Congress 2023
Yonkers, n.y., aug. 28, 2023 (globe newswire) -- contrafect corporation (nasdaq: cfrx), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (dlas), including lysins and amurin peptides, today announces that garrett nichols, m.d., m.s., the company's interim chief medical officer, will be presenting an updated overview of the company's dla programs that target antibiotic-resistant pathogens at the world anti-microbial (amr) congress 2023, which will be held in philadelphia, pa from september 7-8, 2023.
2023-08-14 08:30:00 - Press Release
Contrafect Reports Second Quarter 2023 Financial Results And Provides Business Update
Yonkers, n.y., aug. 14, 2023 (globe newswire) -- contrafect corporation (nasdaq: cfrx), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (dlas), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announces business updates and financial results for the second quarter ended june 30, 2023.
Latest News
2023-10-16 08:19:55 - InvestorPlace
Why Is ContraFect (CFRX) Stock Up 23% Today?
ContraFect (NASDAQ: CFRX ) stock is rising higher on Monday as investors react to an update from the Food and Drug Administration (FDA). The FDA has informed ContraFect that it's good to move forward with a Phase 1 clinical trial of CF-370.
2023-09-19 08:30:00 - GlobeNewsWire
ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development
YONKERS, New York, Sept. 19, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that Jane Ambler, Ph.D., the Company's Vice President of Clinical Microbiology, will be presenting at the ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, which will be held in Boston, MA from September 19-22, 2023.
2023-08-28 08:00:00 - GlobeNewsWire
ContraFect to Present at the World Anti-Microbial Resistance Congress 2023
YONKERS, N.Y., Aug. 28, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that Garrett Nichols, M.D., M.S., the Company's Interim Chief Medical Officer, will be presenting an updated overview of the Company's DLA programs that target antibiotic-resistant pathogens at the World Anti-Microbial (AMR) Congress 2023, which will be held in Philadelphia, PA from September 7-8, 2023.
2023-06-08 16:01:00 - GlobeNewsWire
ContraFect to Present New Data Demonstrating the Potential Efficacy of Its Engineered Lysins Against Antibiotic-Resistant Pathogens at ASM Microbe 2023
YONKERS, N.Y., June 08, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announces that the Company has been selected to present four posters at the ASM Microbe Conference to be held in Houston, Texas from June 15-19, 2023. The data being presented will feature CF-370 demonstrating efficacious activity in a neutropenic rabbit pneumonia model against an extensively-drug-resistant (XDR) strain of Klebsiella pneumoniae (K. pneumoniae).
2023-04-28 06:00:00 - PennyStocks
Discover the Top Penny Stock Technical Indicators By Effectiveness
Use these technical indicators to profit with penny stocks The post Discover the Top Penny Stock Technical Indicators By Effectiveness appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2023-04-18 09:05:43 - InvestorPlace
Why Is ContraFect (CFRX) Stock Down 14% Today?
ContraFect (NASDAQ: CFRX ) stock is dropping on Tuesday after the company revealed a notice from the Nasdaq Exchange. That notice has to do with the continued listing of CFRX stock on the exchange.
2023-04-18 07:00:00 - PennyStocks
The Future of Buying Penny Stocks: Trends for 2023
Use these tips to invest in penny stocks right now The post The Future of Buying Penny Stocks: Trends for 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2023-02-28 06:00:00 - PennyStocks
Penny Stock Investing for Passive Income: Opportunities and Risks
Use these tips for making passive income with penny stocks The post Penny Stock Investing for Passive Income: Opportunities and Risks appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2023-01-31 08:27:40 - InvestorPlace
Why Is ContraFect (CFRX) Stock Up 20% Today?
ContraFect (NASDAQ: CFRX ) stock is rising higher on Tuesday as investors await news about its potential delisting from the Nasdaq Capital Market. ContraFect last updated investors on Friday about its delisting situation.
2023-01-27 08:38:35 - InvestorPlace
Why Is ContraFect (CFRX) Stock Down 23% Today?
ContraFect (NASDAQ: CFRX ) stock is falling on Friday after the company provided an update on its potential delisting from the Nasdaq Capital Market. ContraFect notes in a filing with the SEC that the Nasdaq staff has rejected its request for continued listing on the exchange.